DRMA
Dermata Therapeutics Inc
NASDAQ: DRMA · HEALTHCARE · BIOTECHNOLOGY
$1.37
+8.73% today
Updated 2026-04-30
Market cap
$4.99M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-8.16
Dividend yield
—
52W range
$1 – $10
Volume
1.8M
Dermata Therapeutics Inc (DRMA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.92M | $-4.03M | $-5.69M | $-8.83M | $-6.41M | $-11.16M | $-7.76B |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $730.00 | $0.00 | $1.91M | $930325.00 | $522082.00 | $657649.00 | $143.73M |
| Free cash flow | $-3.92M | $-4.03M | $-5.69M | $-8.83M | $-6.41M | $-11.16M | $-7.76B |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | $2.29M | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |